6:24 PM
 | 
Sep 02, 2009
 |  BC Extra  |  Clinical News

Lodotra meets RA endpoint

Nitec Pharma AG (Reinach, Switzerland) said Lodotra met the primary endpoint of significantly...

Read the full 54 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >